133 related articles for article (PubMed ID: 38579289)
1. Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report.
Pilia AM; Salvati L; Guidolin A; Mazzoni F; Antonuzzo L; Parronchi P; Liotta F
Swiss Med Wkly; 2024 Mar; 154():3513. PubMed ID: 38579289
[TBL] [Abstract][Full Text] [Related]
2. Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report.
De Backer E; Gremonprez F; Brusselle G; Depuydt P; Van Dorpe J; Van Haverbeke C; Goeminne PC; Derom E
Acta Clin Belg; 2018 Dec; 73(6):413-417. PubMed ID: 29287518
[TBL] [Abstract][Full Text] [Related]
3. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
4. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
Yeung TW; Cheong KN; Lau YL; Tse KN
Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
[TBL] [Abstract][Full Text] [Related]
5. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis.
Zhang X; Zhou S; Wu C; Li M; Wang Q; Zhao Y; Zeng X
Rheumatology (Oxford); 2021 Jul; 60(7):e227-e228. PubMed ID: 33410494
[No Abstract] [Full Text] [Related]
7. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
8. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Hosono Y; Mimori T; Kawakami A
Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
[TBL] [Abstract][Full Text] [Related]
9. [Dermatomyositis associated with anti-MDA5 autoantibody].
Collado MV; Gargiulo MLÁ; Gómez R; Gómez G; Pérez N; Suarez L; Taratuto AL; Aruj P
Medicina (B Aires); 2018; 78(5):360-363. PubMed ID: 30285929
[TBL] [Abstract][Full Text] [Related]
10. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
12. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review.
González-Moreno J; Raya-Cruz M; Losada-Lopez I; Cacheda AP; Oliver C; Colom B
Rheumatol Int; 2018 Jul; 38(7):1293-1296. PubMed ID: 29417209
[TBL] [Abstract][Full Text] [Related]
13. [Severe MDA5 dermatomyositis associated with cancer and controlled by JAK inhibitor].
Jalles C; Deroux A; Tardieu M; Lugosi M; Viel S; Benveniste O; Colombe B
Rev Med Interne; 2020 Jun; 41(6):421-424. PubMed ID: 32192753
[TBL] [Abstract][Full Text] [Related]
14. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
J Dermatol; 2020 May; 47(5):483-489. PubMed ID: 32096271
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
16. Eyelid edema as first manifestation of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease: A case report.
Ludriksone L; Pfeil A; Schliemann S; Elsner P
J Dtsch Dermatol Ges; 2020 Mar; 18(3):263-265. PubMed ID: 31922645
[No Abstract] [Full Text] [Related]
17. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
[TBL] [Abstract][Full Text] [Related]
18. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
So H; Wong VTL; Lao VWN; Pang HT; Yip RML
Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
[TBL] [Abstract][Full Text] [Related]
20. [Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies].
Gerfaud-Valentin M; Ahmad K; Piegay F; Fabien N; Raphanel B; Cordier JF; Cottin V
Rev Mal Respir; 2014 Nov; 31(9):849-53. PubMed ID: 25433590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
